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PLATELET AND COAGULATION FUNCTION in relation to thromboembolic stroke is far from fully elucidated. 1 The preventive treatment of cerebral thromboembolism is a matter of debate. No entirely satisfactory link has emerged between present pharmacological knowledge and clinical application of platelet antiaggregatory drugs. 2 Most therapeutic approaches are based on the assumption that the homeostasis between platelet thromboxane, TXA 2 , 3 and vascular prostacyclin PGI 2 , 4 is essential for the hemostatic balance.
One way of interfering with the formation of platelet aggregating and vasoconstricting TXA 2 is by cyclooxygenase inhibition, another by thromboxane synthetase inhibition.
2 - 3 The cyclo-oxygenase inhibitors block the formation of vascular PGI 2 as well as platelet TXA 2 . It has been proposed that thromboxane synthetase inhibitors, besides more selectively limiting the formation of TXA 2 , could in vivo divert the accumulated proaggregatory endoperoxides towards increased formation of platelet antiaggregating and vasodilating PGD 2 and PGI 2 i.e. enhance the negative feedback mechanism. 3 ' 6 Platelet aggregates have previously been observed in cortical surface arteries and in intracerebral precapillary arterioles after infusion of platelet aggregating sodium arachidonate into the carotid artery of rabbits and rats. 7 " 9 The cerebral blood flow and the electroencephalographic activity was reduced. Pretreatment of the heparinized rats with aspirin, i.e. a cyclo-oxygenase inhibitor, strongly reduced arachidonate-induced platelet aggregation in vitro but offered little protection against arachidonate-induced stroke.*
The purpose of our study was to investigate if the thromboxane synthetase inhibitor OKY-1581 prevented cerebral transmission and energy failure induced by an intracarotid infusion of sodium arachidonate, which provokes cerebral thromboembolism and cerebrovascular occlusions-flow reduction in unpretreated rats.
The previously described experimental model was slightly modified -sodium arachidonate was infused into the internal carotid artery of non-heparinized rats to avoid any confounding influence from an anti-clotting agent.
Material and Methods

Animals
The experiments were performed on male Wistar rats (SFP strain, M0llegaards Avlslaboratorium) weighing between 320 and 380 g. The animals had free access to tap water and food pellets until operation.
Chemicals
A 33 mM solution of sodium arachidonate (Chemicon) in 50 mM sodium carbonate in saline was prepared as described by Furlow and Bass, 8 stored at -50° to -70°C and warmed to + 23°C immediately before usage. OKY-1581 (Sodium-3-4(3-pyridylmethyl)phenyl-2-methylacrylate) kindly provided by Kissei Pharmaceutical Co Ltd was dissolved in KrebsHensleit solution to a concentration of 30 mg/ml. Heparin (Vitrum) was diluted to a concentration of 300 IU/ml by Krebs-Hensleit solution.
Platelet Aggregation
The platelet aggregating activity of the sodium arachidonate solution and the interference by heparin and OKY-1581 on aggregate formation was checked on platelet rich plasma from a separate group of rats in an aggregometer according to Bom 10 as modified by Thomgren and Gustavsson." Nine ml of blood was mixed with one ml of 3.8% trisodium citrate in siliconized glass tubes and centrifuged at 260 G for 10 minutes at room temperature immediately after collection (Centrifuge Hettich EBA 3 S). The platelet rich plasma was separated and after further centrifuging at 2600 G for 20 minutes the platelet poor plasma was collected and later used as reference. The platelets were counted 
Operative Technique
The animals were initially anesthetized with 3% halothane and thereafter with 1% in N 2 O/O 2 (7030) via a face mask. Temperature was kept close to 37.5°C by external heating. For the selective and non-occlusive infusion of sodium arachidonate or saline into the internal carotid artery the pterygopalatine artery was ligated and the right external carotid artery was cannulated in retrograde direction leaving the tip of the catheter 1-2 mm from the carotid bifurcation ( fig. 1) . A femoral artery was cannulated to obtain continuous recording electromanimetrically (Elema) of mean arterial blood pressure (MAP) and for blood sampling. A femoral vein was cannulated for the i.v. administration of chemicals. The animals were tracheotomized and connected to a Starling type respirator delivering 1% halothane in N 2 O/O 2 (70:30). Immobilization was accomplished by d-tubocurarine (Vitrum) 1.7 mg/kg. Four goldplated copper bolts were inserted into the skull bone in fixed bilateral frontal and parietal positions for electrophysiological recording. Two needle electrodes were positioned 5-7 mm apart subcutaneously in the whisker areas for electrical stimulation. Thereafter the halothane but not the nitrous oxide supply was terminated. One hour later the experiment was performed after arterial blood samples had been analyzed for blood gases, pH, blood glucose and hematocrit. The animals were replenished with fluid for losses incurred throughout the operative procedure. An intracarotid injection of Krebs-Hensleit solution (50 yu. 1) was invariably done in all animals before the main intracarotid infusion. If the electrophysiological parameters were affected by this injection -presumably due to the release of a preformed thrombus at the tip of 
Electrophysiological Techniques
The electroencephalogram (EEG) was continuously recorded separately from each hemisphere on an Elema Mingograph. The bipolar frontoparietal lead on the injected side was fed into a Cerebral Function Monitor (CFM, Devices Ltd) plotting the EEG through a frequency selective filter (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . 12 CFM provides greater amplification with increasing wave frequency measuring quantitatively changes in the amplitude of the EEG. Somatosensory evoked responses (SER) were recorded contralateral to electrical stimulation of the whisker area as previously described by Agardh et al. 13 The amplitude of the SER was measured from the initial positive to the following negative peak (parietal electrode) and the latency was measured to each of these two peaks. The SER was recorded before and after any injection into the carotid artery.
Experimental Groups
The experiments were performed while the animals were under continuous electroencephalographic recording. Fifteen minutes after a slow infusion of 1 mg sodium arachidonate (1 mg, 100 fil, 1 fxl/s) into the right carotid artery the brain was frozen in situ 14 (n.9). Another experimental group was pretreated with OKY-1581, 30 mg/kg i.v., fifteen minutes before the sodium arachidonate injection (n.6). In an unpretreated control group (n.4) equal amount of Krebs-Hensleit solution (100 jLil) was infused into the right carotid artery instead of sodium arachidonate. In an additional control group (n.3) no intracarotid injection was made before the brain was frozen. Due to technical difficulties, i.e. splitting of the brain when chiselled out of the skull bone, two animals were excluded from analysis of energy metabolites.
Brain Tissue Analysis
The frozen brain was chiselled out at liquid nitrogen temperature and stored at -80°C until analysis of energy metabolites. Tissue samples from the lateral part of the parietal cortex and from the caudate-putamen were dissected and weighed separately at -20°C. The tissue was extracted at this temperature with HC1-methanol and subsequently with perchloric acid at 0°C. The extracts were neutralized with a KOH-imidazole base-KCl mixture as previously described.
1516
The contents of phosphocreatine (PCr), ATP, ADP, AMP, lactate, pyruvate and glucose were analyzed by enzymatic fluorometric techniques. For details of the procedure see Folbergrova et al 15> 16 and Lowry and Passonneau. 17 
Calculations
The energy charge of the adenine nucleotide pool (EC) was calculated according to Atkinsson. 18 Statistical analysis were performed with Fisher's exact probability test, Mann-Whitney U-test and analysis of variance (ANOVA). Values are given as mean ± standard deviation (SD). 
Results
Platelet Aggregation
Platelet aggregation was provoked within seconds by a minimal concentration of 170 /x.g sodium arachidonate per ml platelet rich plasma. Pretreatment of the rats with heparin (n.2), 270 IU/kg i.v., augmented the platelet aggregating effect of 3.3 mM sodium arachidonate (V max = 6%/s) while pretreatment with OKY-1581 (n.2), 30 mg/kg i.v., rendered the platelets less sensitive to arachidonate (V max = 0,1 %/s) compared to nonpretreated rats (V max 1%/s) ( fig. 2 ).
Physiological Parameters
Body temperature, arterial blood gases, pH, blood glucose, hematocrit and blood pressure measured before any intracarotid infusion was made did not differ signficantly among the groups (analysis of variance, 95% probability level). MAP decreased transiently from 156 ± 14 to 129 ± 20 mm Hg in the sodium arachidonate injected animals. In the OKY-1581 pretreated rats MAP decreased from 152 ± 17 to 128 ± 21 mm Hg after the sodium arachidonate administration. In rats infused with Krebs-Hensleit solution MAP was unaffected by the intracarotid injection.
Neural Transmission
The SER was eliminated on the injected side in seven out of nine animals when recorded five and fifteen minutes after the infusion of sodium arachidonate (p < 0.01 compared to the non-injected unaffected hemisphere, Fisher's exact probability test). A tran- 
FIGURE 2. Platelet aggregation, induced by sodium arachidonate (NaA) added to platelet rich plasma in an aggregometer, was measured as maximal change in light transmission per time unit. Pretreatment of the rats with heparin augmented the platelet aggregating effect of NaA while pretreatment with the thromboxane synthetase inhibitor OKY-1581 attenuated platelet aggregation compared to the nonpretreated rats.
sient decrease of the SER-amplitude was seen in one rat five minutes after the infusion. In another rat the SER-amplitude was unaffected. The SER-elimination was accompanied by a reduction of the CFM-amplitude ipsilaterally sometimes preceeded by a short increase. The EEG showed varying abnormality with episodic delta waves contralaterally or bilaterally and/or ipsilateral amplitude depression ( fig. 3 ). SERelimination or depression of the CFM-amplitude was not seen in rats (n.4) infused with equal amount of saline (p < 0.05 compared to the sodium arachidonate injected group) or in rats without any intracarotid infusion (n.3). Rats (n.6) pretreated with OKY-1581 before the sodium arachidonate infusion did not show SER-elimination (p < 0.01 compared to the nonpretreated sodium arachidonate group). Transient decrease of the SER-amplitude was seen in three rats. The rat showing the most marked effect on SER is shown in figure 4 . In the three other rats the SERamplitude was entirely unaffected.
Cerebral Energy Metabolites
The values of the tissue energy charge and lactate in the parietal cortex and the caudate-putamen of both hemispheres are shown in figure 5 . The controls are presented as one group in the figure. In the parietal cortex of the injected hemispheres of the non-pretreated sodium arachidonate infused animals, the energy charge was significantly decreased and the lactate concentration significantly increased compared to the contralateral hemisphere. The lactate level was significantly increased in the caudate-putamen. In the parietal cortex and the caudate-putamen of the noninjected hemispheres the values were similar to those of controls. No interhemispherical differences in energy charge, concentrations of labile phosphates, lactate or pyruvate was observed in the parietal cortex of rats pretreated with OKY-1581 and the values were similar to those of the controls. In the caudate-putamen a small but significant increase in lactate concentration was noted on the injected side (Mann-Whitney U-test).
Discussion
The endothelium forms a non-reactive interface between the artery wall and blood elements such as the platelets." The thrombo-resistance of the endothelium is due to i.a. synthesis of PGI 2 20 and the presence of a heparinlike proteoglucan 21 which combines with antithrombin III adsorbed to the surface. 22 After endothelial injury platelets adhere to exposed subintimal tissue such as collagen and aggregates are formed. Vasoactive, platelet aggregating and proclotting substances are released from the platelets in a potent secretory cascade promoting thrombosis and hemostasis. 23 In experimental cerebral platelet thromboembolism a hemostatic imbalance is created by endothelial damage and/or local accumulation of platelet aggregating agents. A wide variety of substances other than collagen change the shape of the platelet from a smooth surfaced disc to a sphere with pseudopodia facilitating platelet aggregation. One such substance is arachidonic acid acylated to phospholipids in the cell mem- branes. An excessive release of arachidonic acid might in addition to platelet aggregation induce endothelial damage and dysfunction. 24 " 26 Thus, by infusing sodium arachidonate into the carotid artery the homeostasis between vascular PGI 2 and platelet TXA 2 is disturbed promoting platelet aggregate formation 7 "
9 due to excessive TXA 2 .
The activation pathways for platelet aggregation include a complex interrelationship between arachidonic acid metabolites, cyclic nucleotides and calcium within the platelets. 5 - 23> 27 Arachidonic acid can be oxidized by the enzyme cyclo-oxygenase to form endoperoxides. The endoperoxides serve as precursors for the synthesis of the prostaglandins PGD 2 , PGE 2 and PGF 2o< but are in the platelet mainly converted to the highly unstable intermediate TXA 2 by a thromboxane synthetase.
3 TXA 2 is a powerful stimulant of vascular smooth muscle and a potent inducer of platelet aggregation.
The formation of platelet PGD 2 and vascular PGI 2 from the endoperoxides seems to be an important negative feedback mechanism limiting growth of platelet aggregates and vasoconstriction.
Besides decreasing the formation of TXA 2 , thromboxane synthetase inhibitors might augment the negative feedback mechanism limiting the growth of platelet thrombi as stated in the introduction. Heparin has been proposed to attenuate this feedback mechanism and increase the formation of TXA 2 .
28 ' 29 Opposing effects of OKY-1581 and heparin on arachidonate induced platelet aggregation was shown in the present study ( fig. 2 ). Heparin should, however, by binding to antithrombin III and increasing the rate at which this protein inhibits the clotting enzymes, decrease the formation of fibrin strands and the consolidation of platelet aggregates. Because of this and the complex interaction between platelet aggregation and clotting, non-heparinized rats were used to test the prophylactic effect of pretreatment with the thromboxane synthetase inhibitor OKY-1581. The intracarotid infusion of sodium arachidonate provoke a severe reduction of cerebral blood flow within the injected hemisphere, as previously shown with the 14C-antipyrine autoradiographic technique. 9 In some instances small areas of oligemia were found in the territory of the contralateral anterior cerebral artery but the main blood flow reduction occurred within the ipsilateral hemisphere. When injecting small amounts of arachidonate (0.35 mg/kg during 15 sec.) the cerebral circulation was gradually restored after 15 and 45 minutes respectively. We have measured cerebral blood flow with the 14C-iodoantipyrine autoradiographic technique 31 ' 32 in a few rats with ipsilateral SER-elimination 5 (n.l) and 15 (n.4) minutes after the intracarotid infusion of sodium arachidonate (1 mg, 100 fxl, 1 //,1/s). The distribution of cerebral blood flow reduction confirmed previous findings, the degree of oligemia varied considerably between animals and regions (unpublished observations).
The existence of two critical thresholds of cerebral blood flow has been recognized, one for the abolishment of synaptic transmission (transmission failure) and the other, somewhat lower, for the derangement of membrane ion potentials and energy metabolism (membrane failure).
33
" 35 Because heparinization of the animals is necessary for the proper performance of the 14C-iodoantipyrine technique we choose to test the protective effect of the thromboxane synthetase inhibitor OKY-1581 on SER and cerebral energy state using non-heparinized rats. We wanted to see if OKY-1581 preserved the cerebral blood flow above both the threshold for transmission failure and for energy failure when tested without the confounding influence of an anticlotting agent.
The intracarotid infusion of platelet aggregating sodium arachidonate (1 mg) provoked ipsilateral elimination of evoked potentials, degradation of labile phosphates and an increase in lactate in the parietal cortex. The heterogeneity and variability was reflected by the fact that the energy metabolites of the caudateputamen in spite of marked interhemispherical differences of the mean values reached statistical significance only for lactate. Pretreatment of the rats with 36 Furthermore, there are alternative platelet activation pathways not including TXA 2 formation, stimulated by high concentrations of other platelet aggregating agents e.g. collagen and thrombin. 5 -23 Further studies using different platelet aggregating agents are needed to elucidate the possible prophylactic role of thromboxane synthetase inhibition.
